Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2010
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2010
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2015
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2015
Lead Product(s) : Clofarabine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2014
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2012
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Celgene Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2012
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi | Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2011
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi | Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2011
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2011
Lead Product(s) : Clofarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
